Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent

Hepatocellular Carcinoma Clinical Trial

Official title:

A Multicenter, Open-label, Dose Escalation and Expansion, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PB101 in Patients With Advanced Solid Tumor

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06075849
• Other study ID #: PB101_101
• Status: Recruiting
• Phase: Phase 1
• Start date: October 25, 2023
• Est. completion date: January 2025

Study information

• Verified date: February 2024
• Source: Panolos Bioscience
• Contact: Jin A Shin, PhD
• Phone: +82)31-8055-0886
• Email: jashin[@]panolos.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have progressed after standard of care. PB101 may stop the growth of tumor cells by blocking blood flow to the tumor and modulating the tumor microenvironment.

Description:

Primary Objectives To assess the safety and tolerability of PB101 and determine the maximum tolerated dose (MTD) and/or the recommended phase-2 dose Secondary Objectives 1. To characterize the pharmacokinetics of PB101. 2. To identify the preliminary anti-tumor activity of PB101. 3. To assess the immunogenicity of PB101. Tertiary Objectives To explore the correlation between potential pharmacodynamic (PD) biomarkers (e.g., vascular endothelial growth factor(VEGF)-A, placental growth factor (PlGF) and VEGFR1 signaling) and anti-cancer activity of PB101.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: January 2025
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

Subjects must meet all of the following inclusion criteria.

1. =19 years of age

2. Patients with unresectable locally advanced or metastatic solid tumor, confirmed histologically and cytologically, who is refractory to existing standard of care or has progressive disease and has no other available standard of care available.

3. Patient who has at least one measurable or non-measurable but evaluable lesion that meets the RECIST version 1.1.

4. Patient whose expected survival period is 12 weeks or longer.

5. Patient with eastern cooperative oncology group (ECOG) performance status = 2

6. Patient whose adequate hematological function, and kidney and liver functions have been confirmed by the following criteria. (Laboratory tests are allowed to re-conducted within the screening period.)

7. Patient with adequate anticoagulant functions according to the following criteria:

• Without receiving anticoagulant therapy, patient whose international normalized ratio (INR) is = 1.5 x upper limit of normal (ULN) and partial thromboplastin time (PTT) is = 5 seconds above the ULN.
• When receiving an oral anticoagulant or low molecular weight heparin, patient whose prothrombin time (PT) or PTT is confirmed to be stable for at least 2 weeks.
• When receiving warfarin, patient whose INR is =3.0 There must be no active bleeding (bleeding within 14 days) or pathological conditions with a high risk of bleeding (e.g., tumor with macrovesicular invasion or known varicose vein).

8. Patient who voluntarily gave informed consent in writing to participate in this clinical trial after being provided with information on the nature and risks of the study as well as the expected desirable benefits and AEs of the investigative product (IP). Exclusion Criteria: Patients who meet any of the following criteria cannot participate in this clinical trial.

1. Patient expected to show hypersensitivity to the active ingredient and components of PB101 or similar drugs.

2. Patient with the following medical history (including surgery/procedure history) confirmed.

• Major surgery within 4 weeks prior to administration of the IP, and clinically significant traumatism.
• Cardiovascular disease (including unstable angina, myocardial infarction, stroke, and transient ischemic attack), congestive heart failure (NYHA class III or IV), or clinically significant arrhythmia uncontrollable by medication within 24 weeks prior to administration of the IP.
• Patient whose left ventricular ejection fraction (LVEF) measured by echocardiography, multigated blood pool scan (MUGA) scan or the standard procedure at the institution before administration of the IP is less than the lower limit of normal at the institution. However, if there is no reference LVEF set at the institution, 50% will be treated as the reference level.
• Vascular disorders (e.g., deep vein thrombosis, pulmonary embolism, aortic aneurysm, and peripheral arterial thrombosis) within 24 weeks prior to administration of the IP
• Life-threatening (Grade 4) venous thromboembolism (regardless of the duration, even if it is a past medical history)
• Medical history of primary malignancies other than indication for this clinical

trial. However, the following cases are allowed:

• Not less than 3 years have passed since the cure diagnosis of a primary malignancy. However, in case of papillary thyroid cancer, patients who underwent curative resection can participate in the study regardless of the duration.
• At least 1 year has passed since complete resection of cutaneous basal cell carcinoma/squamous cell carcinoma of the skin or successful treatment of cervical carcinoma in situ.
• Psychiatric disorder that may significantly affect the participation in the study at the discretion of the investigator.

3. Patient with the following comorbidities confirmed at the time of participation in the study.

• Squamous cell carcinoma of the lung (current and past medical history).
• Interstitial lung disease or pulmonary fibrosis (current and past medical history).
• The following hemorrhage-related and digestive system diseases (current and past medical history).
• Evidence of active bleeding, hemorrhagic diathesis, coagulopathy, and tumor with macrovesicular invasion.
• Clinically significant medical history of digestive system, such as peptic ulcer, gastrointestinal bleeding, gastrointestinal or non-gastrointestinal fistulas or perforations, intra-abdominal abscesses, clinical symptoms and signs of gastrointestinal obstruction, and inflammatory bowel disease.
• Clinically significant pericardial effusion, pleural fluid, or ascites. However, in case of ascites, patients who do not require paracentesis for improvement of the symptoms can participate in the study.
• Uncontrolled hypertension (systolic blood pressure (SBP) > 150 or diastolic blood pressure (DBP) > 90 mmHg even after medication).
• Infection of active hepatitis B* or C† virus *Hepatitis B surface antigen (HBsAg)-positive at screening. However, for HBsAg positive, not excluded if the patient is taking antiviral agents stably. †Hepatitis C virus antibody (HCV Ab)-positive at screening. However, if the result of HCV RNA test is negative, participation is possible.
• Human immunodeficiency virus (HIV)-positive.
• Severe infection or other uncontrolled active infection that requires administration of systemic antibiotics, antivirals, etc. at the discretion of the investigator
• New or active brain metastases. However, patients who do not need central nervous system (CNS) treatment immediately (or within 1 cycle) at the discretion of the investigator can participate in the study.
• Leptomeningeal metastasis
• Serious and unhealed wound or fracture

4. Patient who received the following treatment regimens (drug/non-drug)

• patient who received the following anti-cancer treatments other than this IP.
• Chemotherapy, hormone therapy, and radiation therapy within 2 weeks prior to administration of the IP. However, patients who completed local radiotherapy as a palliative therapy for the purpose of pain relief in areas other than the target lesion (e.g., site of bone metastases) and recovered from following acute toxicity (e.g., myelosuppression).However, patients who completed local radiotherapy as a palliative therapy for the purpose of pain relief in areas other than the target lesion (e.g., site of bone metastases) and recovered from following acute toxicity (e.g., myelosuppression).However, patients who completed local radiotherapy as a palliative therapy for the purpose of pain relief in areas other than the target lesion (e.g., site of bone metastases) and recovered from following acute toxicity (e.g., myelosuppression).
• Targeted therapies or immunotherapy within 4 weeks prior to administration of the IP.
• Administration history of nitrosoureas or mitomycin-C within 6 weeks prior to administration of the IP.
• Administration history of nonsteroidal anti-inflammatory drugs (NSAID) and anti-platelet agents within 7 days prior to administration of the IP. However, for aspirin, doses of 325 mg/day are allowed.

5. Patient who participated in another clinical study within 4 weeks prior to administration of the IP and received (underwent procedure of) an investigational drug (or medical device).

6. Patient who continues to experience a clinically significant toxicity or adverse event of Grade 2 or higher (based on NCI-CTCAE v5.0) after prior anti-cancer therapy. However, hair loss (any grade) and neuropathy (Grade 2 or lower) are exceptions.

7. Pregnancy test positive at screening, or pregnant or lactating woman.

8. Female or male subject of childbearing potential who does not agree to stay abstinent or use an effective method of contraception† during the study period and for at least 26 weeks (women) or 14 weeks (men) after the last dose of the IP.

†Effective method of contraception:

• Hormonal contraceptive: Subdermal implants, injections, oral contraceptives, etc. However, in case of ovarian/breast cancer, hormonal contraception is not allowed.
• Implantation of an intrauterine device or intrauterine system: Loop, and hormone-containing intrauterine system.
• Sterilization procedure or surgery of the subject or his/her spouse (partner):

Vasectomy, tubal ligation, etc.

9. Other patients deemed ineligible to participate in the study by the investigator.

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Gastric Cancer
• Hepatocellular Carcinoma
• Metastatic Colorectal Cancer
• Neoplasms
• Solid Tumor
• Solid Tumor, Adult

Intervention

Drug:
• PB101
Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs. Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator.

Locations

Country	Name	City	State
Korea, Republic of	CHA University Bundang Medical Center	Seongnam
Korea, Republic of	Seoul National University Bundang Hospital	Seongnam
Korea, Republic of	The Catholic University of Korea Seoul St. Mary's Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Panolos Bioscience

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (2)

Go EJ, Yang H, Lee SJ, Yang HG, Shin JA, Lee WS, Lim HS, Chon HJ, Kim C. PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis. Oncoimmunology. 2023 Sep 20;12(1):2259212. doi: 10.1080/2162402X.2023.2259212. eCollection 2023. — View Citation

Lee JE, Kim C, Yang H, Park I, Oh N, Hua S, Jeong H, An HJ, Kim SC, Lee GM, Koh GY, Kim HM. Novel glycosylated VEGF decoy receptor fusion protein, VEGF-Grab, efficiently suppresses tumor angiogenesis and progression. Mol Cancer Ther. 2015 Feb;14(2):470-9. doi: 10.1158/1535-7163.MCT-14-0968-T. Epub 2014 Dec 22. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Area under the concentration-time curve (AUC)	AUC last, AUC inf	8 weeks
Other	Maximum plasma concentration (Cmax)	For each time point by dose group, number of subjects, mean, standard deviation, and median, minimum, and maximum values will be presented for continuous variables, and frequency and percentage will be presented for categorical variables.	8 weeks
Other	Minimum plasma concentration (Cmin)	For each time point by dose group, number of subjects, mean, standard deviation, and median, minimum, and maximum values will be presented for continuous variables, and frequency and percentage will be presented for categorical variables.	8 weeks
Other	Time to Cmax (Tmax)	For each time point by dose group, number of subjects, mean, standard deviation, and median, minimum, and maximum values will be presented for continuous variables, and frequency and percentage will be presented for categorical variables.	8 weeks
Other	Terminal half-life (t1/2)	For each time point by dose group, number of subjects, mean, standard deviation, and median, minimum, and maximum values will be presented for continuous variables, and frequency and percentage will be presented for categorical variables.	8 weeks
Other	Biomarkers	Serum vascular endothelial growth factor (VEGF) - A, placental growth factor (PlGF), and VEGF receptor 1 (VEGFR1) measurements by dose group and visit	8 weeks
Other	Immunogenicity	Anti-PB101 antibody analysis	8 weeks
Primary	Dose limiting toxicity (DLT)	Frequency by dose group	8 weeks
Primary	Permanent discontinuation / dose reduction due to adverse events (AE)	Frequency and percentage by dose group due to adverse drug reactions (ADR)	8 weeks
Primary	Adverse events	Incidence by dose group for treatment-emergent adverse events (TEAEs), ADRs, serious adverse events (SAEs), and serious ADRs	8 weeks
Primary	Electrocardiogram (ECG)	Clinically significant changes in ECG results compared to baseline	8 weeks
Primary	Left ventricular ejection fraction (LVEF)	Multigated blood pool scan (MUGA) or echocardiography (ECHO), clinical significance and significant changes evaluated	8 weeks
Secondary	Objective response rate (ORR)	Frequency according to response evaluation criteria in solid tumors (RECIST) v1.1	8 weeks
Secondary	Duration of response (DOR)	Time analyzed using Kaplan-Meier method	8 weeks
Secondary	Progression free survival (PFS)	Time analyzed using Kaplan-Meier method	8 weeks
Secondary	Disease control rate (DCR)	Time analyzed using Kaplan-Meier method	8 weeks
Secondary	Time to progression (TTP)	Time analyzed using Kaplan-Meier method	8 weeks
Secondary	Overall survival (OS)	Time analyzed using Kaplan-Meier method	8 weeks
Secondary	Tumor Evaluations	Tumor response will be evaluated according to RECIST v1.1	8 weeks

External Links

•   Company link
•   Mechanism of Action